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Ischemic stroke
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ABSTRACT
Background Limited efﬁcacy of IV recombinant tissue
plasminogen activator (rt-PA) for large vessel occlusions
(LVO) raises doubts about its utility prior to endovascular
therapy.
Purpose To compare outcomes and hospital costs for
anterior circulation LVOs (middle cerebral artery, internal
carotid artery terminus (ICA-T)) treated with either
primary endovascular therapy alone (EV-Only) or bridging
therapy (IV+EV)).
Methods A single-center retrospective analysis was
performed. Clinical and demographic data were collected
prospectively and relevant cost data were obtained for
each patient in the study.
Results 90 consecutive patients were divided into
EV-Only (n=52) and IV+EV (n=38) groups. There was
no difference in demographics, stroke severity, or clot
distribution. The mean (SD) time to presentation was
5:19 (4:30) hours in the EV-Only group and 1:46
(0:52) hours in the IV+EV group ( p<0.0001).
Recanalization: EV-Only 35 (67%) versus IV+EV 31
(81.6%) ( p=0.12). Favorable outcome: EV-Only 26
(50%) versus IV+EV 22 (58%) ( p=0.45). For patients
presenting within 4.5 hours (n=64): Recanalization:
EV-Only 21/26 (81%) versus IV+EV 31/38 (81.6%)
( p=0.93). Favorable outcome: EV-Only 14/26 (54%)
versus IV+EV 22/38 (58%) ( p=0.75). There was no
signiﬁcant difference in rates of hemorrhage, mortality,
home discharge, or length of stay. A stent retriever
was used in 67 cases (74.4%), with similar
recanalization, outcomes, and number of passes in the
EV-Only and IV+EV groups. The mean (SD) total
hospital cost was $33 810 (13 505) for the EV-Only
group and $40 743 (17 177) for the IV+EV group
( p=0.02). The direct cost was $23 034 (8786) for the
EV-Only group and $28 711 (11 406) for the IV+EV
group ( p=0.007). These signiﬁcantly higher costs
persisted for the subgroup presenting in <4.5 hours
and the stent retriever subgroup. IV rt-PA
administration independently predicted higher hospital
costs.
Conclusions IV rt-PA did not improve recanalization,
thrombectomy efﬁcacy, functional outcomes, or length
of stay. Combined therapy was associated with
signiﬁcantly higher total and direct hospital costs than
endovascular therapy alone.

INTRODUCTION
An estimated 24 patients per 100 000 people per
year in the USA have an acute ischemic stroke (AIS)
secondary to a large vessel occlusion (LVO).1 These
strokes are more severe and are less likely to
respond to IV administered therapies than other
types of ischemic stroke.2–5 A number of trials have
shown improved outcomes following endovascular
therapy for LVO strokes compared with standard
therapies alone.6–10 However, the number of
patients treated without prior IV recombinant
tissue plasminogen activator (rt-PA) was small. The
question of whether IV rt-PA before rapid endovascular treatment helps or harms the patient with
LVO stroke therefore remains unanswered. It is
possible that IV rt-PA prior to mechanical therapies
has no effect on the outcome of LVO strokes, as
shown by two recent meta-analyses.11 12 If this is
the case, then the additional cost of IV rt-PA may
be burdensome to the patients and their insurers as
a 100 mg vial of alteplase (Activase, Genentech,
San Francisco, California, USA) used in the preparation of an IV dose for stroke thrombolysis costs
our hospital $7800; 2 years ago the cost was
$6000.
Patients with an LVO may do better with IV
thrombolysis compared with no treatement7 8 13
so, in the absence of endovascular therapy, IV rt-PA
for LVO strokes may be justiﬁed. However, when
endovascular therapy is readily available, the rationale for administering this drug to all patients with
LVO without a proven beneﬁt can be questioned.
Trials conﬁrming the superior efﬁcacy of mechanical thrombectomy did not show an increased risk
of symptomatic intracranial hemorrhage with endovascular therapy following IV thrombolysis.6–8 This
lack of harm may not be sufﬁcient justiﬁcation to
maintain the current standard since a complete definition of harm includes the cost to society—a true
measure of which also includes the opportunity
cost of the therapeutic approach. In total these can
be substantial, considering the multiple other steps
in the stroke chain that can be improved with additional resources. In the evolving landscape for
ischemic stroke treatment, a paradigm change
might be required to reﬂect the current evidence—
a paradigm that includes socioeconomic aspects of
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delivering that care. There may be an adjunctive role for
pharmacological thrombolysis; however, it is possible that the
thrombolytic agent, such as rt-PA, is more efﬁcacious when
administered IA in conjunction with mechanical thrombectomy
than the IV administration of a larger dose.
This study asks two questions: (1) Is there a signiﬁcant difference in hospital costs for patients receiving endovascular stroke
therapy following IV thrombolysis compared with endovascular
therapy alone? (2) Are the procedural and clinical outcomes
better if a patient receives IV rt-PA prior to endovascular
therapy?

METHODS
The study was performed after institutional review board
approval as a single-center retrospective analysis. This is primarily a pilot study conducted in order to evaluate feasibility, potentially determine effect size, and guide larger scale studies.

Patient selection
A prospectively maintained database was searched for endovascular therapy (with or without prior IV rt-PA) for anterior circulation LVO over a 3-year period. We restricted the study to the
recent 3-year period because of improved and more consistent
thrombectomy techniques and the use of next generation
devices. Another reason to limit the study to the recent 3-year
period was implementation of a new, robust and accurate ﬁnancial analytics system that was introduced at the beginning of this
study period. All patients with suspected AIS at our institution
undergo an immediate non-contrast CT (NCCT), a CT angiogram (CTA), and a CT perfusion (CTP) study regardless of their
eligibility for IV rt-PA. Patients presenting with an occlusion
involving the internal carotid artery terminus (ICA-T) or the
main stem of the middle cerebral artery (MCA) with or without
bifurcation branch involvement prospectively identiﬁed on the
CTA were included. Patients with posterior circulation occlusions were excluded because the efﬁcacy of endovascular
therapy has not been shown to be superior to IV thrombolysis
in randomized trials. Patients in both groups, regardless of time
from symptom onset, were selected for endovascular therapy
based on stroke severity, baseline functional status, comorbid
conditions, and imaging ﬁndings of salvageable brain based on
NCCT Alberta Stroke Program Early CT Score (ASPECTS)14 as
well as CTP.15 16 Patients with an LVO presenting within
4.5 hours of symptom onset received IV rt-PA (unless contraindicated) followed by endovascular treatment. If there were contraindications to IV rt-PA (as listed in the Results section), the
patients were treated with endovascular therapy directly. The
patients were divided into two groups: endovascular therapy
following IV rt-PA administration (IV+EV) and endovascular
therapy alone (EV-Only).

Cost analysis
Our hospital assigns costs on an observed cost methodology
using Vizient’s Clinical Data Base (https://vizientinc.com). Every
item on a master price list of devices, medications, supplies, procedures, and other services has a corresponding revenue code.
These revenue codes are periodically updated by the Centers for
Medicare and Medicaid and the National Uniform Billing
Committee. The total charges for each discharge are grouped by
the revenue code and multiplied by the cost–charge ratio, giving
an unadjusted observed direct cost. The cost–charge ratios are
calculated from an individual facility’s cost report data reﬂected
in the Medicare Cost Reports (MCR) (https://www.cms.gov/
Research-Statistics-Data-and-Systems/Downloadable-Public-Use2 of 6

Files/Cost-Reports/), with separate cost–charge ratios for direct
and total costs. The unadjusted observed direct cost is multiplied
by a wage index, relevant to the geographic location of the hospital, applied to the labor portion of the unadjusted cost to
obtain the adjusted observed cost.
Hospital costs for all patients in the study were obtained
using the above described methodology. The total hospital costs
are made up of direct and indirect costs. Direct costs speciﬁc to
each case proﬁle include the costs that are directly related to
patient care such as medications (eg, alteplase), devices (eg, stent
retrievers), procedures, supplies, and technologists’ and nurses’
compensation. Indirect costs are not directly related to patient
care and generally include capital and building costs, utilities,
support services, and overheads. The following parameters
constituted endpoints for cost analysis and were compared
between the IV+EV and the EV-Only groups: total hospital
costs; direct hospital costs; and indirect hospital costs. Since the
length of stay is a signiﬁcant predictor of hospital costs,17 we
also included length of hospital stay and length of intensive care
unit (ICU) stay.

Outcome analyses
Functional outcome
The primary endpoint for treatment efﬁcacy was the 90-day
modiﬁed Rankin score dichotomized into a favorable outcome
(0–2) and poor outcome (3–6).

Procedural outcomes
The primary procedural endpoint was vascular recanalization,
deﬁned as Thrombolysis In Cerebral Ischemia (TICI), with a
grade of 2B or higher considered as successful recanalization.
The number of thrombectomy ‘passes’ was evaluated for
patients in whom a stent retriever was used. We did this for the
stent retriever group as it was the overwhelmingly dominant
device used in our practice.

Safety outcomes
The safety parameters assessed were intracranial hemorrhage
based on the ECASS-II criteria18 19 ( parenchymal hematoma
PH-1 or PH-2 deﬁned as signiﬁcant hemorrhage) and 90-day
mortality.

Statistical analysis
The signiﬁcance of simple bivariate associations was assessed
using Fisher’s exact test for categorical variables, Student’s t-test
for continuous variables, or logistic regression, as appropriate.
The normality of the cost distribution data assessed with the
Shapiro-Wilk W test showed a non-normal distribution of cost
(p<0.0001). The differences in cost between the two groups
were thus assessed using the non-parametric Wilcoxon rank sum
test. All data analysis was performed using JMP statistical software V.11 (SAS Institute, Cary, North Carolina, USA).
Analyses comparing costs and outcomes were performed for
the following groups: (1) the entire cohort; (2) patients presenting within 4.5 hours of symptom onset (ie, those eligible for IV
thrombolysis); and (3) patients in whom a stent retriever was
used.

RESULTS
Outcome analyses for the entire cohort and the
≤4.5 hours subgroup
A total of 90 consecutive patients satisﬁed the above described
inclusion criteria. Of these, 52 patients (58%) were in the
EV-Only group and 38 (42%) were in the IV+EV group. The
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baseline statistics presented in table 1 show that the two groups
were similar in demographic make-up, stroke severity, and
comorbidities. The only signiﬁcant difference was a longer time
to presentation from symptom onset for the EV-Only group.
The CT-Interventional Neuroradiology (INR) Lab time trended
to be lower in the EV-Only group, but the procedure duration
was similar for both groups. For the entire cohort, successful
recanalization was achieved in 66 patients (73.3%, 95% CI 63%
to 81%) and a favorable outcome was seen in 48 (53.3%, 95%
CI 43% to 63%). Recanalization was a signiﬁcant predictor of
outcome, with a favorable outcome seen in 42/66 patients (64%)
with successful recanalization compared with 6/24 patients (25%)
with failed recanalization (OR 0.19, 95 CI 0.07 to 0.54,
p=0.001). There was no difference in outcomes between the IV
+EV and EV-Only groups either in patients with successful recanalization or those with failed recanalization: among patients
with successful recanalization (n=66), a favorable outcome was
seen in 22/35 patients (63%) in the EV-Only group versus 20/31
patients (64.5%) in the IV+EV group (p=0.88). In patients with
failed recanalization (n=24), a favorable outcome was seen in 4/
17 patients (23.5%) in the EV-Only group versus 2/7 patients
(28.6%) in the IV+EV group ( p=0.8).
A comparison of the clinical, procedural, and safety outcomes
did not show any difference between the two groups for recanalization, favorable outcome, signiﬁcant hemorrhage, mortality,
or home discharge—either for the entire cohort or for the subgroup presenting within 4.5 hours of symptom onset (ie, those
within the therapeutic time window for IV rt-PA) (table 2). The
reasons for patients who presented within 4.5 hours undergoing
endovascular therapy without IV rt-PA (n=26) included recent
stroke or hemorrhage (n=6), anticoagulation therapy (n=5),
recent surgical procedure (n=3), abnormal platelets or coagulation (n=2), metastatic cancer (n=1), a nonagenarian presenting
at 4 hours (n=1), and patients who were barely within the time
window on arrival but would have been outside before the
bolus could be administered (n=8).

presented in table 3. The table shows that the direct and total
hospital costs were signiﬁcantly higher for the IV+EV group.
There was no signiﬁcant difference in the indirect costs, indicating that the driver for increased hospitals costs is the direct cost
component. The length of hospital stay was signiﬁcantly correlated with total hospital cost (R2 0.59, p<0.0001). The hospital
costs were higher in the IV+EV group than in the EV-Only
group despite a similar length of total hospital stay and stay in
the ICU. Among the outcomes, recanalization, length of stay
and treatment type, IV+EV treatment ( p=0.002 for total cost,
p=0.0007 for direct cost), and longer length of hospital stay
(p<0.0001 for both total and direct costs) remained independent predictors of higher total and direct costs on logistic
regression.

Stent retriever subgroup
Sixty-seven patients (74.4%) were treated using a stent retriever.
An aspiration catheter was used as the primary thrombectomy
device in seven patients (7.8%). In 16 patients (17.8%) no
thrombectomy device was used either due to inaccessible
anatomy (n=11) or clot lysis/migration (n=5). Clot lysis prior
to intervention was observed in three patients (5.7%) in the
EV-Only group and two (5.3%) in the IV+EV group. The distribution of the devices was stent retriever in 36 patients
(69.2%), aspiration in 4 (7.7%), and no device in 12 patients
(23.1%) in the EV-Only group versus stent retriever in 31
patients (81.6%), aspiration in 3 (7.9%), and no device in 4
patients (10.5%) in the IV+EV group ( p=0.28). In order to
remove the effects of device choice on outcomes and cost, we
conducted a separate analysis for only those patients in whom a
stent retriever was used (n=67, table 4). This analysis showed
that, for similar stroke severity and clot distribution, there was
no signiﬁcant difference between the rate of recanalization and
favorable outcomes between the two groups; however, the total
and direct costs remained signiﬁcantly higher for the IV+EV
group. There was no difference in the number of stent retriever
thrombectomy passes made between the two groups (ﬁgure 1).

Cost comparison
A comparison of the total, direct, and indirect hospital costs for
the entire cohort as well as the ≤4.5 hours subgroup is
Table 1 Baseline demographics, comorbidities and treatment
times

DISCUSSION
The systems of care for endovascular stroke therapy are evolving
following positive trials.6–10 Successful outcomes after mechanical thrombectomy depend to a large degree on the speed and

EV-Only (n=52) IV+EV (n=38)
Age, mean (SD)
Female patients, n (%)
ICA-T, n (%)/MCA, n (%)
Diabetes, n (%)
Hypertension, n (%)
Hyperlipidemia, n (%)
Atrial fibrillation, n (%)
Smoking, n (%)
NIHSS, median (IQR)
CT ASPECTS
Mean (SD) time from
symptom onset, hour:min
Mean (SD) CT–INR, hour:min
Mean (SD) procedure
duration, hour:min

69
32
8
15
38
27
24
12
16
7.5
5:19

(18)
63 (19)
0.15
(61)
18 (47)
0.18
(15)/44 (85)
4 (10.5)/34 (89.5) 0.5
(29)
7 (18)
0.25
(73)
21 (55)
0.08
(52)
17 (45)
0.5
(46)
10 (26)
0.052
(23)
5 (13.)
0.23
(10–22)
18 (13–23)
0.08
(6–9)
8 (7–9)
0.09
(4:30)
1:46 (0:52)
<0.0001*

0:47 (0:32)
1:11 (0:33)

1:00 (0:33)
1:16 (0:37)

0.054
0.47

*Significance level is set at 0.05.
EV-Only, endovascular therapy alone group; ICA-T, internal carotid artery terminus;
IV+EV, endovascular therapy following IV rt-PA administration group; MCA,
middle cerebral artery; NIHSS, NIH Stroke Scale.
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Table 2 Functional and safety outcomes for the entire cohort and
for the subgroup presenting within 4.5 hours of symptom onset
EV-Only vs IV+EV
Onset to
presentation
≤4.5 hours (n=64)

EV-Only vs IV+EV
Entire cohort
(n=90)

Recanalization
Favorable
outcome
Hemorrhage
(PH1/PH2)
Mortality
Home
discharge

EV-Only
(n=52)

IV+EV
(n=38)

35 (67)
26 (50)

31 (81.6) 0.12
22 (58)
0.45

3 (5.8)

1 (2.6)

EV-Only
p Value (n=26)

0.46

13 (25)
4 (10.5) 0.07
19 (36.5) 11 (29)
0.45

21 (81)
14 (54)
1 (3.8)

IV+EV
(n=38)

p Value

31 (81.6) 0.93
22 (58)
0.75
1 (2.6)

0.78

5 (19.2) 4 (10.5) 0.33
11 (42)
11 (29)
0.27

All values shown are n (%).
EV-Only, endovascular therapy alone group; IV+EV, endovascular therapy following IV
rt-PA administration group.
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Table 3 Comparison of length of stay and hospital costs between the two treatment groups
EV-Only vs IV+EV
Onset to presentation ≤4.5 hours
(n=64)

EV-Only vs IV+EV
Entire cohort (n=90)

Total cost, $
Direct cost, $
Indirect cost, $
Length of stay, days
Length of ICU stay, days†

EV-Only (n=52)

IV+EV (n=38)

p Value

EV-Only (n=26)

IV+EV (n=38)

p Value

33 810 (13 505)
23 034 (8786)
10 777 (5104)
8 (6)
2.1 (2.1)

40 743
28 711
12 032
8
2.2

0.024*
0.007*
0.39
0.86
0.48

31 621 (12 874)
22 087 (9228)
9534 (3928)
6 (4)
2 (2.2)

40 743 (17 177)
28 711 (11 406)
12 032 (6311)
8 (6)
2.2 (1.5)

0.027*
0.017*
0.09
0.34
0.23

(17 177)
(11 406)
(6311)
(6)
(1.5)

All values shown are mean (SD).
*Significance level is set at 0.05.
†ICU stay comparison is for 39 patients in the EV-Only group and 30 patients in the IV+EV group for the entire cohort and 20 patients in the EV-Only group and 30 patients in the IV
+EV group for the ≤4.5 hours cohort.
EV-Only, endovascular therapy alone group; ICU, intensive care unit; IV+EV, endovascular therapy following IV rt-PA administration group.

efﬁciency with which recanalization is achieved. The key determinant in triaging a patient with AIS is rapid identiﬁcation of an
LVO, which is now possible with modern multidetector CT
scanners. Once an LVO is identiﬁed in a patient with favorable
clinical and imaging parameters, all resources should be directed
at achieving revascularization. In this setting, diverting attention
and resources to administering IV rt-PA, which may or may not
have an effect on the outcome but does add to the costs, needs
to be re-examined. IV rt-PA did not improve recanalization or
favorable outcomes in our patients, despite the signiﬁcantly
longer time to presentation for the EV-Only group. This is
because we rely heavily on tissue-based patient selection using
NCCT and CTP as opposed to a time clock. To remove the
effect of time, we conducted a separate analysis of patients presenting within 4.5 hours and found nearly identical rates of
recanalization and favorable outcomes.
Frequent arguments in favor of administering IV rt-PA before
endovascular therapy include possible enhancement of the interventional procedure and at least some possibility of a good
outcome in case of unsuccessful recanalization. In our study,
administration of IV rt-PA did not improve revascularization or
functional outcomes. There was higher mortality in the
EV-Only group, although this was not statistically signiﬁcant.
This difference could be partly due to the complexity of the
case mixture between the groups or procedural variables that we
did not measure. It is possible that the difference in mortality
would become signiﬁcant in a larger sample or that the

Table 4 Comparison of outcomes and costs for patients in whom
a stent retriever was the primary thrombectomy device (n=67)

NIHSS, median (IQR)
CT ASPECTS, median (IQR)
ICA-T/MCA, n (%)
Recanalization, n (%)
Favorable outcome, n (%)
Mean (SD) total cost, $
Mean (SD) direct cost, $
Mean (SD) indirect cost, $

EV-Only (n=36)

IV+EV (n=31)

17 (10–24)
7 (6–8)
5 (14)/31 (86)
29 (80.6)
19 (53)
33 999 (11 394)
23 429 (7534)
10 570 (4355)

18 (11–24)
8 (7–9)
3 (9.7)/28 (90.3)
27 (87.1)
18 (58)
41 420 (17 155)
29 269 (11 287)
12 150 (6443)

0.38
0.02*
0.59
0.46
0.66
0.027*
0.007*
0.38

*Significance level is set at 0.05.
ASPECTS, Alberta Stroke Program Early CT Score; EV-Only, endovascular therapy alone
group; ICA-T, internal carotid artery terminus; IV+EV, endovascular therapy following
IV rt-PA administration group; MCA, middle cerebral artery; NIHSS, NIH Stroke Scale.
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difference would be diminished in a larger, better matched
sample. There was no difference in the number of thrombectomy passes or procedure duration. The failure to improve outcomes was not dependent on whether or not recanalization was
achieved. Thus, the notion that IV rt-PA could provide some
beneﬁt in cases where there is failure of recanalization was not
borne out by our data. These results did not change for patients
presenting within 4.5 hours or those treated with a stent
retriever. Our ﬁndings are in keeping with a recent study20 and
meta-analyses11 12 showing no beneﬁt of IV thrombolysis prior
to endovascular therapy.
This study shows signiﬁcantly higher total and direct hospital
costs for patients who received IV rt-PA before endovascular
therapy. These costs remained signiﬁcantly higher for patients
presenting within 4.5 hours and for those treated with a stent
retriever. There was no difference in indirect costs between
these groups, indicating that the reason for higher total costs is
the direct rather than the indirect cost. As mentioned in the
Methods section, direct costs represent the costs of services and
supplies directly involved in patient care. This is important
because the cost of medications such as alteplase and devices
such as stent retrievers is reﬂected in the direct costs. The fact
that direct costs remained signiﬁcantly higher for the IV+EV
group despite similar demographics, similar length of total and
ICU stay, similar device use, and similar outcomes indicates that
the cost of IV alteplase ($7800 for our hospital) was the main
driver of higher direct costs in the group receiving bridging
therapy. Along with a longer length of stay, the use of IV rt-PA
independently predicted higher hospital costs. In fact, the difference in average total and direct costs was roughly equal to the
cost of alteplase. The price of stent retrievers is similar to that
of alteplase and it is possible that, as the stent retriever market
saturates, a product may differentiate itself with a lower price.
Additionally, aspiration-only techniques may incur lower direct
costs than stent retrievers,21 thus both a lower-priced thrombectomy device and increased use of aspiration techniques can
further increase the cost gap with bridging therapy. Of course,
the use of multiple devices or a decrease in the price of alteplase
can offset these dynamics.
The majority of payer mix in our catchment population is
Medicare, so the cost of care is an important consideration
when expanding services or expediting delivery of stroke interventions.22 Endovascular therapy for LVO strokes has been associated with a ﬁnancial beneﬁt to the hospital over IV
thrombolysis.17 A detailed analysis from the UK showed mechanical thrombectomy to be cost effective based on the quality
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adjusted gain in life years,23 and a similar cost analysis from the
USA showed a signiﬁcant reduction in the ﬁnancial burden of
stroke with endovascular therapy compared with IV rt-PA for
large vessel strokes.24 A randomized clinical trial evaluating the
efﬁcacy of IV rt-PA for large vessel strokes versus medical management has never been done and is probably not possible
anymore. It may not be prudent to completely eliminate IV
rt-PA since there is indirect evidence that, in the absence of anything else, IV rt-PA could be beneﬁcial for LVO strokes.
Endovascular interventions are resource-intensive around the
clock therapies that are ideally suited for large comprehensive
centers, not just because of the cost of care involved but also
because of the critical supportive services required for optimal
postoperative management and improved functional outcomes.
Operator experience in higher volume comprehensive centers
also correlates with better outcomes after stroke interventions.25
The neurointerventional workforce is estimated to be more than
sufﬁcient to meet the current and expected demand for endovascular stroke coverage.26 27 It may therefore be practical to
organize stroke care along the ST-elevation myocardial infarction guidelines28 29—that is, develop systems for efﬁcient transfer of patients to endovascular-capable hospitals where primary
mechanical thrombectomy is the preferred treatment modality
and reserve IV thrombolysis if access to a comprehensive center
is not readily available. A randomized clinical trial showing clear
beneﬁt of thrombectomy alone over thrombectomy following
IV thrombolysis may be required to take this next step in large
vessel stroke care.

Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
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effect not discernible in our study. There may be selection biases
in our data that we have not accounted for, and this is a singlecenter experience with a large rural catchment population.
Hospital costs vary based on geography, size, and level of care,
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CONCLUSION
IV thrombolysis prior to endovascular therapy did not improve
recanalization rates, procedure duration, number of thrombectomy passes, length of admission, or functional outcomes over
endovascular therapy alone in this pilot study. These observations held true for patients presenting within 4.5 hours of
symptom onset. IV rt-PA use was associated with signiﬁcantly
higher total and direct hospital costs, with direct costs being the
driver for this difference. As systems evolve, a tiered treatment
paradigm similar to acute coronary care may serve as a useful
model for endovascular stroke therapy.
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